{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:43:09Z","timestamp":1793191389749,"version":"4.5.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,9]],"date-time":"2020-09-09T00:00:00Z","timestamp":1599609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100013995","name":"Sanofi Genzyme","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100013995","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Diabetes is common in patients with rheumatoid arthritis (RA). Interleukin (IL)-6 is implicated in both the pathogenesis of RA and in glucose homeostasis; this post hoc analysis investigated the effects of IL-6 receptor vs. tumour necrosis factor inhibition on glycosylated haemoglobin (HbA1c) in patients with RA with or without diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Data were from two placebo-controlled phase III studies of subcutaneous sarilumab 150\/200\u2009mg q2w\u2009+\u2009methotrexate or conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) and a phase III monotherapy study of sarilumab 200\u2009mg q2w vs. adalimumab 40\u2009mg q2w. Patients with diabetes were identified by medical history or use of antidiabetic medication (patients with HbA1c \u2265\u20099% were excluded from all three studies). HbA1c was measured at baseline and weeks 12\/24. Safety and efficacy were assessed in RA patients with or without diabetes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Patients with diabetes (<jats:italic>n<\/jats:italic>\u2009=\u2009184) were older, weighed more and exhibited higher RA disease activity than patients without diabetes (<jats:italic>n<\/jats:italic>\u2009=\u20091928). Regardless of diabetes status, in patients on background csDMARDs, least squares (LS) mean difference (95% CI) in change from baseline in HbA1c for sarilumab 150\u2009mg\/200\u2009mg vs. placebo at week 24 was \u2212\u20090.28 (\u2212\u20090.40, \u2212\u20090.16; nominal<jats:italic>p<\/jats:italic>\u2009&lt;\u2009\u00a00.0001) and \u2212\u20090.42 (\u2212\u20090.54, \u2212\u20090.31; nominal<jats:italic>p<\/jats:italic>\u2009&lt;\u2009\u00a00.0001), respectively. Without csDMARDs, LS mean difference for sarilumab 200\u2009mg vs. adalimumab 40\u2009mg at week 24 was \u2212\u20090.13 (\u2212\u20090.22, \u2212\u20090.04; nominal<jats:italic>p<\/jats:italic>\u2009=\u20090.0043). Greater reduction in HbA1c than placebo or adalimumab was observed at week 24 with sarilumab in patients with diabetes and\/or baseline HbA1c \u2265\u20097%. There was no correlation between baseline\/change from baseline in HbA1c and baseline\/change from baseline in C-reactive protein, 28-joint Disease Activity Score, or haemoglobin, nor between HbA1c change from baseline and baseline glucocorticoid use. Medical history of diabetes or use of diabetes treatments had limited impact on safety and efficacy of sarilumab and was consistent with overall phase III findings in patients with RA.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In post hoc analyses, sarilumab was associated with a greater reduction in HbA1c than csDMARDs or adalimumab, independent of sarilumab anti-inflammatory effects. Prospective studies are required to further assess these preliminary findings.<\/jats:p><\/jats:sec><jats:sec><jats:title>Trial registration<\/jats:title><jats:p>ClinTrials.gov NCT01061736: date of registration February 03, 2010; ClinTrials.gov NCT01709578: date of registration October 18, 2012; ClinTrials.gov NCT02332590: date of registration January 07, 2015.<\/jats:p><\/jats:sec>","DOI":"10.1186\/s13075-020-02229-5","type":"journal-article","created":{"date-parts":[[2020,9,10]],"date-time":"2020-09-10T14:02:09Z","timestamp":1599746529000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Interleukin-6 receptor blockade or TNF\u03b1 inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5294-4503","authenticated-orcid":false,"given":"Mark C.","family":"Genovese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerd R.","family":"Burmester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Owen","family":"Hagino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karthinathan","family":"Thangavelu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melitza","family":"Iglesias-Rodriguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory St","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel A.","family":"Gonz\u00e1lez-Gay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Mandrup-Poulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roy","family":"Fleischmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,9]]},"reference":[{"issue":"2","key":"2229_CR1","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1093\/rheumatology\/kex414","volume":"57","author":"K Albrecht","year":"2018","unstructured":"Albrecht K, Luque Ramos A, Hoffmann F, et al. High prevalence of diabetes in patients with rheumatoid arthritis: results from a questionnaire survey linked to claims data. Rheumatology (Oxford). 2018;57(2):329\u201336.","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2229_CR2","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1002\/art.20878","volume":"52","author":"H Maradit-Kremers","year":"2005","unstructured":"Maradit-Kremers H, Nicola PJ, Crowson CS, et al. Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum. 2005;52(3):722\u201332.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2229_CR3","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jbspin.2016.09.001","volume":"84","author":"J Nicolau","year":"2017","unstructured":"Nicolau J, Lequerre T, Bacquet H, et al. Rheumatoid arthritis, insulin resistance, and diabetes. Joint Bone Spine. 2017;84(4):411\u20136.","journal-title":"Joint Bone Spine"},{"key":"2229_CR4","doi-asserted-by":"publisher","first-page":"k1497","DOI":"10.1136\/bmj.k1497","volume":"362","author":"G Xu","year":"2018","unstructured":"Xu G, Liu B, Sun Y, et al. Prevalence of diagnosed type 1 and type 2 diabetes among US adults in 2016 and 2017: population based study. BMJ. 2018;362:k1497.","journal-title":"BMJ"},{"issue":"3","key":"2229_CR5","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1002\/art.38986","volume":"67","author":"JT Giles","year":"2015","unstructured":"Giles JT, Danielides S, Szklo M, et al. Insulin resistance in rheumatoid arthritis: disease-related indicators and associations with the presence and progression of subclinical atherosclerosis. Arthritis Rheumatol. 2015;67(3):626\u201336.","journal-title":"Arthritis Rheumatol"},{"issue":"3","key":"2229_CR6","first-page":"1000019","volume":"2","author":"A Urman","year":"2018","unstructured":"Urman A, Taklalsingh N, Sorrento C, et al. Inflammation beyond the joints: rheumatoid arthritis and cardiovascular disease. Scifed J Cardiol. 2018;2(3):1000019.","journal-title":"Scifed J Cardiol"},{"issue":"Suppl 5","key":"2229_CR7","doi-asserted-by":"publisher","first-page":"v3","DOI":"10.1093\/rheumatology\/kes113","volume":"51","author":"E Choy","year":"2012","unstructured":"Choy E. Understanding the dynamics: pathways involved in the pathogenesis of rheumatoid arthritis. Rheumatology (Oxford). 2012;51(Suppl 5):v3\u2013v11.","journal-title":"Rheumatology (Oxford)"},{"key":"2229_CR8","doi-asserted-by":"publisher","first-page":"35242","DOI":"10.1038\/srep35242","volume":"6","author":"YJ Park","year":"2016","unstructured":"Park YJ, Yoo SA, Kim GR, et al. Urinary interleukin-6 as a predictor of radiographic progression in rheumatoid arthritis: a 3-year evaluation. Sci Rep. 2016;6:35242.","journal-title":"Sci Rep"},{"key":"2229_CR9","doi-asserted-by":"publisher","first-page":"698313","DOI":"10.1155\/2014\/698313","volume":"2014","author":"Y Yoshida","year":"2014","unstructured":"Yoshida Y, Tanaka T. Interleukin 6 and rheumatoid arthritis. Biomed Res Int. 2014;2014:698313.","journal-title":"Biomed Res Int"},{"issue":"1","key":"2229_CR10","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/rheumatology\/kep329","volume":"49","author":"JM Dayer","year":"2010","unstructured":"Dayer JM, Choy E. Therapeutic targets in rheumatoid arthritis: the interleukin-6 receptor. Rheumatology (Oxford). 2010;49(1):15\u201324.","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"2229_CR11","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1748-1716.2007.01779.x","volume":"192","author":"S Glund","year":"2008","unstructured":"Glund S, Krook A. Role of interleukin-6 signalling in glucose and lipid metabolism. Acta Physiol. 2008;192(1):37\u201348.","journal-title":"Acta Physiol"},{"issue":"3","key":"2229_CR12","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s10787-018-0458-0","volume":"26","author":"M Akbari","year":"2018","unstructured":"Akbari M, Hassan-Zadeh V. IL-6 signalling pathways and the development of type 2 diabetes. Inflammopharmacology. 2018;26(3):685\u201398.","journal-title":"Inflammopharmacology"},{"issue":"Suppl 2","key":"2229_CR13","doi-asserted-by":"publisher","first-page":"S114","DOI":"10.2337\/diabetes.54.suppl_2.S114","volume":"54","author":"OP Kristiansen","year":"2005","unstructured":"Kristiansen OP, Mandrup-Poulsen T. Interleukin-6 and diabetes: the good, the bad, or the indifferent? Diabetes. 2005;54(Suppl 2):S114\u201324.","journal-title":"Diabetes"},{"issue":"3","key":"2229_CR14","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1001\/jama.286.3.327","volume":"286","author":"AD Pradhan","year":"2001","unstructured":"Pradhan AD, Manson JE, Rifai N, et al. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327\u201334.","journal-title":"JAMA"},{"issue":"3","key":"2229_CR15","doi-asserted-by":"publisher","first-page":"812","DOI":"10.2337\/diabetes.52.3.812","volume":"52","author":"J Spranger","year":"2003","unstructured":"Spranger J, Kroke A, Mohlig M, et al. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Diabetes. 2003;52(3):812\u20137.","journal-title":"Diabetes"},{"issue":"1","key":"2229_CR16","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1042\/bj2720243","volume":"272","author":"C Southern","year":"1990","unstructured":"Southern C, Schulster D, Green IC. Inhibition of insulin secretion from rat islets of Langerhans by interleukin-6. An effect distinct from that of interleukin-1. Biochem J. 1990;272(1):243\u20135.","journal-title":"Biochem J"},{"issue":"2","key":"2229_CR17","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1210\/endo-126-2-1288","volume":"126","author":"S Sandler","year":"1990","unstructured":"Sandler S, Bendtzen K, Eizirik DL, et al. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vitro. Endocrinology. 1990;126(2):1288\u201394.","journal-title":"Endocrinology"},{"issue":"2","key":"2229_CR18","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1016\/j.cyto.2015.05.005","volume":"75","author":"DB Ballak","year":"2015","unstructured":"Ballak DB, Stienstra R, Tack CJ, et al. IL-1 family members in the pathogenesis and treatment of metabolic disease: focus on adipose tissue inflammation and insulin resistance. Cytokine. 2015;75(2):280\u201390.","journal-title":"Cytokine"},{"issue":"2","key":"2229_CR19","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1038\/nri2925","volume":"11","author":"MY Donath","year":"2011","unstructured":"Donath MY, Shoelson SE. Type 2 diabetes as an inflammatory disease. Nat Rev Immunol. 2011;11(2):98\u2013107.","journal-title":"Nat Rev Immunol"},{"issue":"15","key":"2229_CR20","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1056\/NEJMoa065213","volume":"356","author":"CM Larsen","year":"2007","unstructured":"Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007;356(15):1517\u201326.","journal-title":"N Engl J Med"},{"key":"2229_CR21","doi-asserted-by":"crossref","unstructured":"Kataria Y, Ellervik C, Mandrup-Poulsen T. Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients. Semin Immunopathol. 2019.","DOI":"10.1007\/s00281-019-00743-6"},{"key":"2229_CR22","doi-asserted-by":"crossref","unstructured":"Elena C, Chiara M, Angelica B, et al. Hyperglycemia and diabetes induced by glucocorticoids in nondiabetic and diabetic patients: revision of literature and personal considerations. Curr Pharm Biotechnol. 2019;19(15):1210\u20131220.","DOI":"10.2174\/1389201020666190102145305"},{"issue":"5","key":"2229_CR23","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1002\/art.39537","volume":"68","author":"M Movahedi","year":"2016","unstructured":"Movahedi M, Beauchamp ME, Abrahamowicz M, et al. Risk of incident diabetes mellitus associated with the dosage and duration of oral glucocorticoid therapy in patients with rheumatoid arthritis. Arthritis Rheumatol. 2016;68(5):1089\u201398.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"2229_CR24","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1136\/annrheumdis-2016-209954","volume":"76","author":"G Ozen","year":"2017","unstructured":"Ozen G, Pedro S, Holmqvist ME, et al. Risk of diabetes mellitus associated with disease-modifying antirheumatic drugs and statins in rheumatoid arthritis. Ann Rheum Dis. 2017;76(5):848\u201354.","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"2229_CR25","doi-asserted-by":"publisher","first-page":"2525","DOI":"10.1001\/jama.2011.878","volume":"305","author":"DH Solomon","year":"2011","unstructured":"Solomon DH, Massarotti E, Garg R, et al. Association between disease-modifying antirheumatic drugs and diabetes risk in patients with rheumatoid arthritis and psoriasis. JAMA. 2011;305(24):2525\u201331.","journal-title":"JAMA"},{"issue":"1","key":"2229_CR26","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1136\/annrheumdis-2017-211836","volume":"77","author":"C Rempenault","year":"2018","unstructured":"Rempenault C, Combe B, Barnetche T, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with rheumatoid arthritis: a systematic review and meta-analysis. Ann Rheum Dis. 2018;77(1):98\u2013103.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2229_CR27","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1002\/acr.22285","volume":"66","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Garg R, Lu B, et al. Effect of hydroxychloroquine on insulin sensitivity and lipid parameters in rheumatoid arthritis patients without diabetes mellitus: a randomized, blinded crossover trial. Arthritis Care Res. 2014;66(8):1246\u201351.","journal-title":"Arthritis Care Res"},{"key":"2229_CR28","first-page":"6543237","volume":"2017","author":"X Chen","year":"2017","unstructured":"Chen X, Wang N, Zhu Y, et al. The antimalarial chloroquine suppresses LPS-induced NLRP3 inflammasome activation and confers protection against murine endotoxic shock. Mediat Inflamm. 2017;2017:6543237.","journal-title":"Mediat Inflamm"},{"issue":"8","key":"2229_CR29","doi-asserted-by":"publisher","first-page":"2026","DOI":"10.1002\/art.38652","volume":"66","author":"MC de Rotte","year":"2014","unstructured":"de Rotte MC, de Jong PH, den Boer E, et al. Effect of methotrexate use and erythrocyte methotrexate polyglutamate on glycosylated hemoglobin in rheumatoid arthritis. Arthritis Rheumatol. 2014;66(8):2026\u201336.","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"2229_CR30","doi-asserted-by":"publisher","first-page":"347","DOI":"10.3109\/03009742.2015.1105290","volume":"45","author":"K Perdan-Pirkmajer","year":"2016","unstructured":"Perdan-Pirkmajer K, Pirkmajer S, Thevis M, et al. Methotrexate reduces HbA1c concentration but does not produce chronic accumulation of ZMP in patients with rheumatoid or psoriatic arthritis. Scand J Rheumatol. 2016;45(5):347\u201355.","journal-title":"Scand J Rheumatol"},{"issue":"5","key":"2229_CR31","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1136\/annrheumdis-2016-210310","volume":"76","author":"GR Burmester","year":"2017","unstructured":"Burmester GR, Lin Y, Patel R, et al. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial. Ann Rheum Dis. 2017;76(5):840\u20137.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2229_CR32","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/art.39944","volume":"69","author":"R Fleischmann","year":"2017","unstructured":"Fleischmann R, van Adelsberg J, Lin Y, et al. Sarilumab and nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis and inadequate response or intolerance to tumor necrosis factor inhibitors. Arthritis Rheumatol. 2017;69(2):277\u201390.","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"2229_CR33","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1002\/art.39093","volume":"67","author":"MC Genovese","year":"2015","unstructured":"Genovese MC, Fleischmann R, Kivitz AJ, et al. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a phase III study. Arthritis Rheumatol. 2015;67(6):1424\u201337.","journal-title":"Arthritis Rheumatol"},{"issue":"Suppl 1","key":"2229_CR34","doi-asserted-by":"publisher","first-page":"S55","DOI":"10.2337\/dc18-S006","volume":"41","author":"Association AD","year":"2018","unstructured":"Association AD. Glycemic targets: standards of medical care in diabetes\u20142018. Diabetes Care. 2018;41(Suppl 1):S55\u201364.","journal-title":"Diabetes Care"},{"issue":"3","key":"2229_CR35","first-page":"469","volume":"34","author":"JF Simard","year":"2007","unstructured":"Simard JF, Mittleman MA. Prevalent rheumatoid arthritis and diabetes among NHANES III participants aged 60 and older. J Rheumatol. 2007;34(3):469\u201373.","journal-title":"J Rheumatol"},{"issue":"1","key":"2229_CR36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0210459","volume":"14","author":"S Lillegraven","year":"2019","unstructured":"Lillegraven S, Greenberg JD, Reed GW, et al. Immunosuppressive treatment and the risk of diabetes in rheumatoid arthritis. PLoS One. 2019;14(1):e0210459.","journal-title":"PLoS One"},{"issue":"3","key":"2229_CR37","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/JLB.5VMR0118-021RR","volume":"104","author":"LM Frydrych","year":"2018","unstructured":"Frydrych LM, Bian G, O'Lone DE, et al. Obesity and type 2 diabetes mellitus drive immune dysfunction, infection development, and sepsis mortality. J Leukoc Biol. 2018;104(3):525\u201334.","journal-title":"J Leukoc Biol"},{"issue":"5","key":"2229_CR38","first-page":"358","volume":"7","author":"International Hypoglycaemia Study Group","year":"2019","unstructured":"International Hypoglycaemia Study Group. Hypoglycaemia, cardiovascular disease, and mortality in diabetes: epidemiology, pathogenesis, and management. Lancet Diabetes Endocrinol. 2019;7(5):358\u201396.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2229_CR39","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1136\/ard.2010.145839","volume":"70","author":"MT Nurmohamed","year":"2011","unstructured":"Nurmohamed MT, Kitas G. Cardiovascular risk in rheumatoid arthritis and diabetes: how does it compare and when does it start? Ann Rheum Dis. 2011;70(6):881\u20133.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2229_CR40","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1136\/ard.2010.132845","volume":"70","author":"A Ogata","year":"2011","unstructured":"Ogata A, Morishima A, Hirano T, et al. Improvement of HbA1c during treatment with humanised anti-interleukin 6 receptor antibody, tocilizumab. Ann Rheum Dis. 2011;70(6):1164\u20135.","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"2229_CR41","doi-asserted-by":"publisher","first-page":"e0196368","DOI":"10.1371\/journal.pone.0196368","volume":"13","author":"Y Otsuka","year":"2018","unstructured":"Otsuka Y, Kiyohara C, Kashiwado Y, et al. Effects of tumor necrosis factor inhibitors and tocilizumab on the glycosylated hemoglobin levels in patients with rheumatoid arthritis; an observational study. PLoS One. 2018;13(4):e0196368.","journal-title":"PLoS One"},{"key":"2229_CR42","unstructured":"Specker C, Alberding A, Aringer M, et al. Improvement of HbA1c in patients with rheumatoid arthritis and diabetes type 2 during treatment with tocilizumab. 2018."},{"issue":"3","key":"2229_CR43","first-page":"465473","volume":"37","author":"S Castaneda","year":"2019","unstructured":"Castaneda S, Remuzgo-Martinez S, Lopez-Mejias R, et al. Rapid beneficial effect of the IL-6 receptor blockade on insulin resistance and insulin sensitivity in non-diabetic patients with rheumatoid arthritis. Clin Exp Rheumatol. 2019;37(3):465473.","journal-title":"Clin Exp Rheumatol"},{"issue":"12","key":"2229_CR44","doi-asserted-by":"publisher","first-page":"4167","DOI":"10.1210\/jcem.82.12.4422","volume":"82","author":"C Tsigos","year":"1997","unstructured":"Tsigos C, Papanicolaou DA, Kyrou I, et al. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation. J Clin Endocrinol Metab. 1997;82(12):4167\u201370.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2229_CR45","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.1016\/j.cmet.2018.04.008","volume":"27","author":"L Lang Lehrskov","year":"2018","unstructured":"Lang Lehrskov L, Lyngbaek MP, Soederlund L, et al. Interleukin-6 delays gastric emptying in humans with direct effects on glycemic control. Cell Metab. 2018;27(6):1201\u201311 e1203.","journal-title":"Cell Metab"},{"issue":"1","key":"2229_CR46","first-page":"83","volume":"24","author":"MA Gonzalez-Gay","year":"2006","unstructured":"Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2006;24(1):83\u20136.","journal-title":"Clin Exp Rheumatol"},{"issue":"3","key":"2229_CR47","doi-asserted-by":"publisher","first-page":"R141","DOI":"10.1186\/ar3874","volume":"14","author":"I Stagakis","year":"2012","unstructured":"Stagakis I, Bertsias G, Karvounaris S, et al. Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. Arthritis Res Ther. 2012;14(3):R141.","journal-title":"Arthritis Res Ther"},{"issue":"9","key":"2229_CR48","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1007\/s10067-007-0539-8","volume":"26","author":"LS Tam","year":"2007","unstructured":"Tam LS, Tomlinson B, Chu TT, et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. Clin Rheumatol. 2007;26(9):1495\u20138.","journal-title":"Clin Rheumatol"},{"issue":"12","key":"2229_CR49","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1093\/rheumatology\/kew306","volume":"55","author":"LA Bissell","year":"2016","unstructured":"Bissell LA, Hensor EM, Kozera L, et al. Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study. Rheumatology (Oxford). 2016;55(12):2181\u201390.","journal-title":"Rheumatology (Oxford)"},{"issue":"11","key":"2229_CR50","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1055\/s-0031-1287783","volume":"43","author":"I Ferraz-Amaro","year":"2011","unstructured":"Ferraz-Amaro I, Arce-Franco M, Muniz J, et al. Systemic blockade of TNF-alpha does not improve insulin resistance in humans. Horm Metab Res. 2011;43(11):801\u20138.","journal-title":"Horm Metab Res"},{"issue":"2","key":"2229_CR51","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1080\/03009740601179605","volume":"36","author":"A Rosenvinge","year":"2007","unstructured":"Rosenvinge A, Krogh-Madsen R, Baslund B, et al. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNF alpha therapy. Scand J Rheumatol. 2007;36(2):91\u20136.","journal-title":"Scand J Rheumatol"},{"issue":"4","key":"2229_CR52","doi-asserted-by":"publisher","first-page":"R160","DOI":"10.1186\/ar3900","volume":"14","author":"A Stavropoulos-Kalinoglou","year":"2012","unstructured":"Stavropoulos-Kalinoglou A, Metsios GS, Panoulas VF, et al. Anti-tumour necrosis factor alpha therapy improves insulin sensitivity in normal-weight but not in obese patients with rheumatoid arthritis. Arthritis Res Ther. 2012;14(4):R160.","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"2229_CR53","doi-asserted-by":"publisher","first-page":"4023","DOI":"10.2337\/db13-0138","volume":"62","author":"E Bach","year":"2013","unstructured":"Bach E, Nielsen RR, Vendelbo MH, et al. Direct effects of TNF-\u03b1 on local fuel metabolism and cytokine levels in the placebo-controlled, bilaterally infused human leg: increased insulin sensitivity, increased net protein breakdown, and increased IL-6 release. Diabetes. 2013;62(12):4023\u20139.","journal-title":"Diabetes"},{"issue":"1","key":"2229_CR54","doi-asserted-by":"publisher","first-page":"E108","DOI":"10.1152\/ajpendo.00471.2005","volume":"291","author":"R Krogh-Madsen","year":"2006","unstructured":"Krogh-Madsen R, Plomgaard P, Moller K, et al. Influence of TNF-alpha and IL-6 infusions on insulin sensitivity and expression of IL-18 in humans. Am J Physiol Endocrinol Metab. 2006;291(1):E108\u201314.","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"2229_CR55","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1093\/rheumatology\/kel322","volume":"46","author":"JG Boulton","year":"2007","unstructured":"Boulton JG, Bourne JT. Unstable diabetes in a patient receiving anti-TNF-alpha for rheumatoid arthritis. Rheumatology (Oxford). 2007;46:178\u20139.","journal-title":"Rheumatology (Oxford)"},{"key":"2229_CR56","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.1136\/ard.2007.072256","volume":"66","author":"E Bonilla","year":"2007","unstructured":"Bonilla E, Lee YY, Phillips PE, et al. Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus. Ann Rheum Dis. 2007;66:1688.","journal-title":"Ann Rheum Dis"},{"key":"2229_CR57","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1016\/j.jaad.2008.10.009","volume":"60","author":"CG Wambier","year":"2009","unstructured":"Wambier CG, Foss-Freitas MC, Paschoal RS, et al. Severe hypoglycemia after initiation of anti-tumor necrosis factor therapy with etanercept in a patient with generalized pustular psoriasis and type 2 diabetes mellitus. J Am Acad Dermatol. 2009;60:883\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"2229_CR58","doi-asserted-by":"publisher","first-page":"1032","DOI":"10.1016\/j.jaad.2008.12.012","volume":"60","author":"D Cheung","year":"2009","unstructured":"Cheung D, Bryer-Ash M. Persistent hypoglycemia in a patient with diabetes taking etanercept for the treatment of psoriasis. J Am Acad Dermatol. 2009;60(6):1032\u20136.","journal-title":"J Am Acad Dermatol"},{"key":"2229_CR59","unstructured":"Tocilizumab (TCZ) in New-onset Type 1 Diabetes (EXTEND). Accessed on 10th June 2019 [https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02293837]."}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02229-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-020-02229-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-020-02229-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,7]],"date-time":"2023-10-07T04:36:57Z","timestamp":1696653417000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-020-02229-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,9]]},"references-count":59,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["2229"],"URL":"https:\/\/doi.org\/10.1186\/s13075-020-02229-5","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,9]]},"assertion":[{"value":"2 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Protocols for all trials were approved by the appropriate ethics committees\/institutional review boards, and each patient provided written informed consent before participation in their study. The studies were conducted in compliance with institutional review board regulations, the International Conference on Harmonisation Guidelines for Good Clinical Practice and the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MCG has received research grants and consulting fees or other remuneration (payment) from Sanofi Genzyme, Genentech, Roche and R-Pharm.GRB has received research grants from AbbVie, Pfizer, UCB and Roche and has received consulting fees or other remuneration (payment) or participated in speakers\u2019 bureaus from\/for AbbVie, Lilly, Merck Sharp & Dohme, Pfizer, Roche, Sanofi and UCB.TM-P has received consulting fees from Sanofi.OH, MI-R and KT are employees of Sanofi Genzyme and may hold stock and\/or stock options in the company.GSJ is an employee of Regeneron Pharmaceuticals, Inc. and may hold stock and\/or stock options in the company.MAG-G has received research grants and consulting fees from AbbVie, Roche, Sanofi, Eli Lilly and Novartis.RF has received research grants from AbbVie, Acea, Amgen, Bristol-Myers Squibb, Celgene, Celltrion, Genentech, Eli Lilly, GlaxoSmithKline, Pfizer, Roche, Sanofi and UCB and has received consulting fees from AbbVie, Akros Pharma, Amgen, Bristol-Myers Squibb, Eli Lilly, Pfizer, Samsung, Taiho and UCB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"206"}}